RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Emergent BioSolutions Stock

Emergent BioSolutions Net Income 2024

Emergent BioSolutions Net Income

-109.02 M USD

Ticker

EBS

ISIN

US29089Q1058

WKN

A0LC2W

In 2024, Emergent BioSolutions's profit amounted to -109.02 M USD, a -85.67% increase from the -760.5 M USD profit recorded in the previous year.

The Emergent BioSolutions Net Income history

YEARNET INCOME (undefined USD)
2029e-
2028e-2.14
2027e-2.14
2026e-65.2
2025e-61.45
2024e-109.02
2023-760.5
2022-211.6
2021219.5
2020305.1
201954.5
201862.7
201782.6
201651.8
201562.9
201436.7
201331.1
201223.5
201123
201051.7
200931.1
200820.7
200722.9
200622.8
200515.8
200411.5

Emergent BioSolutions Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Emergent BioSolutions, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Emergent BioSolutions from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Emergent BioSolutions’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Emergent BioSolutions. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Emergent BioSolutions’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Emergent BioSolutions’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Emergent BioSolutions’s growth potential.

Emergent BioSolutions Revenue, EBIT and net profit per share

DateEmergent BioSolutions RevenueEmergent BioSolutions EBITEmergent BioSolutions Net Income
2029e999.9 M undefined0 undefined0 undefined
2028e789.62 M undefined11.21 M undefined-2.14 M undefined
2027e761.34 M undefined12.63 M undefined-2.14 M undefined
2026e1.15 B undefined-95.95 M undefined-65.2 M undefined
2025e1.15 B undefined-70.7 M undefined-61.45 M undefined
2024e1.12 B undefined-35.65 M undefined-109.02 M undefined
20231.05 B undefined-201.5 M undefined-760.5 M undefined
20221.12 B undefined-163.3 M undefined-211.6 M undefined
20211.77 B undefined383.1 M undefined219.5 M undefined
20201.56 B undefined480.1 M undefined305.1 M undefined
20191.11 B undefined114.1 M undefined54.5 M undefined
2018782.4 M undefined89.8 M undefined62.7 M undefined
2017560.9 M undefined124.3 M undefined82.6 M undefined
2016488.8 M undefined105.5 M undefined51.8 M undefined
2015489.3 M undefined141.5 M undefined62.9 M undefined
2014404.5 M undefined89.2 M undefined36.7 M undefined
2013312.7 M undefined45.6 M undefined31.1 M undefined
2012281.9 M undefined39.6 M undefined23.5 M undefined
2011273.4 M undefined34.6 M undefined23 M undefined
2010286.2 M undefined76.9 M undefined51.7 M undefined
2009234.8 M undefined40.2 M undefined31.1 M undefined
2008178.6 M undefined29.9 M undefined20.7 M undefined
2007182.9 M undefined33.1 M undefined22.9 M undefined
2006152.7 M undefined38.5 M undefined22.8 M undefined
2005130.7 M undefined37.9 M undefined15.8 M undefined
200483.5 M undefined13 M undefined11.5 M undefined

Emergent BioSolutions stock margins

The Emergent BioSolutions margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Emergent BioSolutions. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Emergent BioSolutions.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Emergent BioSolutions's sales revenue. A higher gross margin percentage indicates that the Emergent BioSolutions retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Emergent BioSolutions's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Emergent BioSolutions's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Emergent BioSolutions's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Emergent BioSolutions. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Emergent BioSolutions's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Emergent BioSolutions Margin History

Emergent BioSolutions Gross marginEmergent BioSolutions Profit marginEmergent BioSolutions EBIT marginEmergent BioSolutions Profit margin
2029e32.77 %0 %0 %
2028e32.77 %1.42 %-0.27 %
2027e32.77 %1.66 %-0.28 %
2026e32.77 %-8.31 %-5.65 %
2025e32.77 %-6.15 %-5.35 %
2024e32.77 %-3.18 %-9.72 %
202332.77 %-19.2 %-72.48 %
202237.98 %-14.61 %-18.94 %
202157.82 %21.6 %12.38 %
202067.42 %30.87 %19.62 %
201960.8 %10.32 %4.93 %
201858.81 %11.48 %8.01 %
201765.11 %22.16 %14.73 %
201673.14 %21.58 %10.6 %
201578.03 %28.92 %12.86 %
201474.78 %22.05 %9.07 %
201380.14 %14.58 %9.95 %
201283.65 %14.05 %8.34 %
201184.56 %12.66 %8.41 %
201083.54 %26.87 %18.06 %
200980.28 %17.12 %13.25 %
200880.91 %16.74 %11.59 %
200777.97 %18.1 %12.52 %
200684.22 %25.21 %14.93 %
200575.82 %29 %12.09 %
200463.95 %15.57 %13.77 %

Emergent BioSolutions Aktienanalyse

What does Emergent BioSolutions do?

Emergent BioSolutions Inc is a biotechnology company specializing in the development of products for protection against biological threats, infectious diseases, and cancer. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland, USA. Emergent BioSolutions' business model is based on developing and marketing innovative products for the protection of public health and national security. The company aims to respond to known and unknown threats and focus on the changing healthcare needs of society. Emergent BioSolutions operates in four business segments: Biosavérica, Vaccines, Therapeutics, and Contract Manufacturing. Biosavérica is a Latin American subsidiary specializing in the distribution of biological products in Central and South America. Vaccines develops and produces vaccines for infectious diseases such as anthrax, cholera, and typhoid. Therapeutics focuses on the development of anti-infectives and cancer therapeutics. Contract Manufacturing offers services to the biopharmaceutical industry, including the manufacturing, development, and analysis of biopharmaceutical products. Emergent BioSolutions' products include vaccines, antitoxins, antibodies, and therapeutics. One of their most well-known products is BioThrax, an anthrax vaccine used by the US government for defense against biological threats since 2002. Other products include the cholera vaccine Vaxchora, the flu medication FluBlok, and the antibody Anthim used for anthrax. Emergent BioSolutions has partnerships with various governments and organizations worldwide, including the US government, the European Commission, and the World Health Organization. This collaboration aims to ensure that Emergent BioSolutions provides products and services in the areas of national security and public health and enables a rapid response in the event of epidemics and pandemics. In recent years, Emergent BioSolutions has also made several acquisitions to strengthen its business. In 2017, they acquired Cangene Corporation, a company specialized in the manufacture of anti-infectives and antitoxins. In 2019, Emergent BioSolutions acquired PaxVax, a company developing vaccines for infectious diseases, and Adapt Pharma, a company specializing in antidotes for opioid overdose. Emergent BioSolutions is a company focused on innovative research and development, offering products for the protection of public health and national security. The company has experienced significant growth in recent years and strives to adapt to the changing healthcare needs of society. Emergent BioSolutions ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Emergent BioSolutions's Profit Margins

The profit margins of Emergent BioSolutions represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Emergent BioSolutions's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Emergent BioSolutions's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Emergent BioSolutions's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Emergent BioSolutions’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Emergent BioSolutions stock

How much profit has Emergent BioSolutions made this year?

Emergent BioSolutions has made -109.02 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -85.67% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Emergent BioSolutions publish its earnings?

Emergent BioSolutions publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Emergent BioSolutions?

The profits of Emergent BioSolutions are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Emergent BioSolutions?

You can learn more about the earnings of Emergent BioSolutions by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Emergent BioSolutions pay?

Over the past 12 months, Emergent BioSolutions paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Emergent BioSolutions is expected to pay a dividend of 0 USD.

What is the dividend yield of Emergent BioSolutions?

The current dividend yield of Emergent BioSolutions is .

When does Emergent BioSolutions pay dividends?

Emergent BioSolutions pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Emergent BioSolutions?

Emergent BioSolutions paid dividends every year for the past 0 years.

What is the dividend of Emergent BioSolutions?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Emergent BioSolutions located?

Emergent BioSolutions is assigned to the 'Health' sector.

Wann musste ich die Aktien von Emergent BioSolutions kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Emergent BioSolutions from 9/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.

When did Emergent BioSolutions pay the last dividend?

The last dividend was paid out on 9/18/2024.

What was the dividend of Emergent BioSolutions in the year 2023?

In the year 2023, Emergent BioSolutions distributed 0 USD as dividends.

In which currency does Emergent BioSolutions pay out the dividend?

The dividends of Emergent BioSolutions are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Emergent BioSolutions stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Emergent BioSolutions

Our stock analysis for Emergent BioSolutions Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Emergent BioSolutions Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.